ABSTRACT
Objectives. To study factors that predict changes in management with digital breast tomosynthesis (DBT). Methods. The Institutional Review Board approved this HIPAA compliant study. 996 patients had DBT with full field digital mammography (FFDM). Univariate analysis evaluated predictors of management change and cancer detection. Results. DBT changed management in 109 of 996 (11%); 77 (71%) required less imaging. Recalled patients after abnormal FFDM screen were most likely to have management change-25% (24 of 97 patients) compared to 8% (13/163) of symptomatic patients and 10% (72/736) of screening patients (P < 0.001). Dense breasted patients had a higher likelihood of having DBT change management: 13% (68/526) compared to 9% (41/470) (P = 0.03). Of the 996 patients, 19 (2%) were diagnosed with breast cancer. 15 cancers (83%) were seen on FFDM and DBT; 3 (17%) were diagnosed after DBT (0.3%, 95%CI: 0.1-0.9%). One recurrence was in the skin and was not seen on DBT nor was it seen on FFDM. The increase in cancer detection rate was 17% for asymptomatic patients, 0% for symptomatic patients, and 100% for recalled patients. Conclusions. DBT increased cancer detection rate by 20% and decreased the recall rate in 8-25%. Advances in Knowledge. DBT led to a doubling of the cancer detection rate in recalled patients.
ABSTRACT
Recombinant oncolytic viruses represent a promising alternative option for the treatment of malignant cancers. We have reported earlier the safety and efficacy of recombinant vesicular stomatitis virus (VSV) vectors in a rat model of hepatocellular carcinoma (HCC). However, the full potential of VSV therapy is limited by a sudden decline in intratumoral virus replication observed early after viral administration, a phenomenon that coincides with an accumulation of inflammatory cells within infected lesions. To overcome the antiviral function of these cells, we present a recombinant virus, rVSV-UL141, which expresses a protein from human cytomegalovirus known to downregulate the natural killer (NK) cell-activating ligand CD155. The modified vector resulted in an inhibition of NK cell recruitment in vitro, as well as decreased intratumoral accumulations of NK and NKT cells in vivo. Administration of rVSV-UL141 through hepatic artery infusion in immune-competent Buffalo rats harboring orthotopic, multi-focal HCC lesions resulted in a one-log elevation of intratumoral virus replication over a control rVSV vector, which translated to enhance tumor necrosis and substantial prolongation of survival. Moreover, these results were achieved in the absence of apparent toxicities. The present study suggests the applicability of this strategy for the development of effective and safe oncolytic agents to treat multi-focal HCC, and potentially a multitude of other cancers, in the future.
Subject(s)
Cytomegalovirus/genetics , Genetic Vectors/therapeutic use , Killer Cells, Natural/immunology , Liver Neoplasms, Experimental/therapy , Lymphocytes, Tumor-Infiltrating/immunology , Natural Killer T-Cells/immunology , Oncolytic Virotherapy , Vesiculovirus/physiology , Animals , Chemotaxis, Leukocyte , Cytopathogenic Effect, Viral , Immunocompetence , Inflammation , Liver Neoplasms, Experimental/immunology , Male , Necrosis , Newcastle disease virus/genetics , Rats , Rats, Inbred BUF , Specific Pathogen-Free Organisms , Vesiculovirus/genetics , Virus ReplicationABSTRACT
Gestational breast cancer (BC) is generally associated with rapid growth and increased mortality. Because the presence of MMTV-like sequences in BC has been associated with laminin receptor expression, a marker of poor prognosis, gestational BCs were analyzed for MMTV env gene-like sequences to explore whether MMTV-like sequences were also associated with its adverse outcome. Whereas 30-38% of sporadic BC have the sequences, in gestational BC the prevalence is 62%. We suggest that hormonal response elements present in the MMTV-like LTR may play a role in promoting cell growth, as they do in the mouse system.
Subject(s)
Breast Neoplasms/virology , Carcinoma, Ductal/virology , Genes, env/genetics , Mammary Tumor Virus, Mouse/genetics , Animals , Breast Neoplasms/genetics , Carcinoma, Ductal/genetics , DNA, Neoplasm , Female , Hormones/pharmacology , Humans , Lactation , Mice , Middle Aged , Neoplasm Invasiveness , Pregnancy , Prognosis , Response Elements , Terminal Repeat Sequences/geneticsABSTRACT
We have shown that interleukin-12 (IL-12) generated a strong, albeit transient, anti-tumor response, mostly mediated by natural killer (NK) cell. T cell participation, in addition to NK cells, was essential for persistence of the anti-tumor response. Ligation of 4-1BB, a co-stimulatory receptor expressed on activated T cells, is known to amplify T cell-mediated immunity. In this study, we compared the effect of a systemically delivered agonistic anti-4-1BB monoclonal antibody (anti-4-1BB mAb) with intra-tumoral adenoviral-mediated gene transfer of the 4-1BB ligand (ADV/4-1BBL) to liver metastases in a syngeneic animal model of breast cancer. Both treatments induced a dramatic regression of pre-established tumor. When combined with intra-tumoral delivery of the IL-12 gene, both anti-4-1BB mAb and ADV/4-1BBL were synergistic and led to survival rates of 87% and 78%, respectively. The anti-tumor immunity is mainly mediated by CD4+ T cells in IL-12 plus 4-1BB ligand-treated animals, and CD8+ T cells in IL-12 plus anti-4-1BB mAb-treated animals. However, only long-term survivors after treatment with IL-12 and 4-1BBL genes have showed significantly potent, systemic, and tumor-specific T cell-mediated immunity.
Subject(s)
Breast Neoplasms/therapy , Genetic Therapy/methods , Immunotherapy/methods , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Adenoviridae/genetics , Animals , Antibodies, Monoclonal/therapeutic use , Antigens, CD , Breast Neoplasms/immunology , Combined Modality Therapy , Female , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Immunity, Cellular , Injections, Intralesional , Interleukin-12/administration & dosage , Liver Neoplasms/immunology , Lymphocyte Activation , Mice , Mice, Inbred BALB C , Receptors, Nerve Growth Factor/immunology , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/immunology , T-Lymphocytes/immunology , Tumor Necrosis Factor Receptor Superfamily, Member 9ABSTRACT
BACKGROUND: PAR is a novel gene ubiquitously expressed in normal and malignant tissues with a trend towards higher expression in tumor cells. PAR biological function is unknown. Here we report the effect of lowering PAR expression on in vitro and in vivo proliferation of DU145 cells. METHODS: Decreased PAR expression was achieved by stable transfection of DU145 cells with antisense PAR cDNA cloned in pCMV-Script expression vector. The proliferative potential of DU145 transfectants was studied by cell counts, colony formation in soft agar, flow cytometry, and growth in severe combined immunodeficient (SCID) mice. RESULTS: DU145 transfectants exhibited a decreased cell proliferation in tissue culture and a low efficiency of colony formation in soft agar. Flow cytometry revealed an arrest of these cells in G2-M phase of mitotic cycle. A dramatic decrease of tumor growth was observed when DU145 transfectant cells were inoculated in SCID mice, compared with controls. Histological examination of these tumors showed a marked decrease in cell density and in number of mitoses while control tumors showed a high cell density and numerous mitoses. CONCLUSIONS: The data presented here provide the first evidence for PAR gene cellular function and its possible implication in malignant transformation.
Subject(s)
Membrane Proteins , Neoplasm Proteins/biosynthesis , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Protein Biosynthesis , Animals , Blotting, Northern , Cell Division , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/pathology , DNA, Antisense/genetics , DNA, Antisense/pharmacology , Flow Cytometry , Gene Expression Regulation, Neoplastic , Histocytochemistry , Humans , Male , Mice , Mice, SCID , Neoplasm Proteins/analysis , Neoplasm Proteins/genetics , Neoplasms, Hormone-Dependent/metabolism , Neoplasms, Hormone-Dependent/pathology , Prostatic Neoplasms/genetics , Proteins/analysis , Proteins/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Random Allocation , Recombinant Proteins/genetics , Specific Pathogen-Free Organisms , Transfection , Tumor Cells, CulturedABSTRACT
Animal studies have shown that direct injection of an adenoviral vector (Adv.RSV-tk) expressing the herpes thymidine kinase gene into established tumors in the liver, followed by systemic ganciclovir administration, was effective in inducing tumor necrosis. Toxicities were minimal at therapeutically effective vector doses, although severe hepatic necroinflammation was seen at much higher supratherapeutic doses. We conducted a clinical phase I trial in patients with metastatic colorectal adenocarcinoma in the liver to assess the safety of intratumoral Adv.RSV-tk injection (escalating doses) followed by intravenous ganciclovir (fixed dose). The vector was injected into a metastatic tumor in the liver under local anesthesia by percutaneous needle placement with concurrent ultrasonographic monitoring to prevent injection or leakage into adjacent normal liver structures. We treated 16 patients in five dose level cohorts of Adv.RSV-tk, from 1.0x10(10) to 1.0x10(13) virus particles per patient. Hepatic toxicities were low, with transient grade 1 elevations in serum aminotransferase levels in 3 of 16 patients. Other toxicities were also transient: grade 2-3 fevers in 5 of 16 patients, grade 3 thrombocytopenia in 1 of 16 patients, and grade 2 leucopenia in 3 of 16 patients. These results indicate that Adv.RSV-tk can be safely administered by percutaneous intratumoral injection in patients with hepatic metastases at doses up to 1.0x10(13) virus particles per patient, and can provide the basis for future clinical trials involving intratumoral adenoviral vector injection.
Subject(s)
Adenoviridae/genetics , Colorectal Neoplasms/pathology , Colorectal Neoplasms/therapy , Genes, Lethal/genetics , Genetic Therapy/methods , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Adult , Aged , Colorectal Neoplasms/genetics , Female , Ganciclovir/adverse effects , Ganciclovir/pharmacology , Humans , Liver Neoplasms/genetics , Male , Middle Aged , Simplexvirus/enzymology , Simplexvirus/genetics , Survival Rate , Thymidine Kinase/antagonists & inhibitors , Thymidine Kinase/genetics , Thymidine Kinase/metabolism , Transduction, Genetic , Treatment OutcomeABSTRACT
BACKGROUND: The maximum tolerated dose (MTD) and efficacy of weekly 1-hour paclitaxel with 3 days of high dose oral estramustine were evaluated in patients with hormone-refractory prostate carcinoma. METHODS: Patients enrolled in cohorts of three received two cycles of six weekly treatments with 1 week of rest: Cohort I received paclitaxel 40 mg/m2 and estramustine 600 mg/m2, and Cohorts II-IV received paclitaxel 60 mg/m2, 75 mg/m2, or 90 mg/m2, respectively, and estramustine 900 mg/m2. Toxicity was assessed weekly, and response was measured by serum prostate specific antigen (PSA), abdominal computed tomography scans, and bone scans at Week 13. RESULTS: Eighteen patients were enrolled, with 12 in Cohorts III and IV. Four patients did not complete treatment. Grade 3 toxicity included one patient with nausea and diarrhea in Cohort III and one patient each with neutropenia and edema followed by Grade 4 thromboembolism in Cohort IV. Grade 1-2 anemia or myelotoxicity were not observed; 3 patients had neuropathy, 5 patients had hair loss, and 8 patients had gastrointestinal symptoms. A decline in the serum PSA level > or = 50% occurred in none of three patients, one of three patients, four of six patients, and four of six patients in Cohorts I-IV, respectively. An intent-to-treat analysis showed responses in 9 of 18 patients (50%) in Cohorts I-IV, with 9 of 15 responders (60%) in Cohorts II-IV. Seven patients achieved declines in serum PSA levels > 75%. The median duration of PSA response was 16.7 weeks. Response was observed in one of three patients with measurable disease. CONCLUSIONS: The MTD for 1-hour weekly paclitaxel was 90 mg/m2 with 3 days of 900 mg/m2 estramustine. Hematologic and neurotoxicity were reduced markedly, and gastrointestinal symptoms were ameliorated, but thromboembolic events were unaffected. PSA response rates were within the expected 60% range for these agents.
Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/drug therapy , Estramustine/pharmacology , Paclitaxel/pharmacology , Prostatic Neoplasms/drug therapy , Administration, Oral , Adult , Aged , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/adverse effects , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/adverse effects , Carcinoma/pathology , Dose-Response Relationship, Drug , Estramustine/administration & dosage , Estramustine/adverse effects , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Paclitaxel/administration & dosage , Paclitaxel/adverse effects , Prostatic Neoplasms/pathology , Treatment OutcomeABSTRACT
The increasing ability to augment antitumor immunity in model systems has led to increased numbers of clinical trials. However, progress in detecting immune responses by patients against autologous tumors has been slow. Although a considerable number of tumor antigens, as well as peptides derived from them, and the MHC determinants together with which they are presented have been identified for melanoma, this is not so for the majority of solid tumors. Furthermore, tumor cells themselves are poor stimulators of immunity. Thus, approaches that do not depend upon defined antigens or using tumor cells as stimulators would be desirable. To attempt to measure immune responses in these situations, we tested whether total peptides, prepared from autologous tumor tissue, stimulated cytokine release by T cells. Peripheral blood mononuclear cells (PBMCs) were mixed with antigen-presenting cells (APCs), pulsed with tumor peptides, and tested in the ELISPOT assay for IFN-gamma secretion. Few spots were obtained when PBMCs were cultured with unpulsed APCs or in wells with peptide-pulsed APC alone. In contrast, a strong response was seen when PBMCs were cultured with APCs that had been pulsed with autologous total tumor peptides. This system should help to identify those immunotherapeutic approaches that induce responses against tumor cells in vivo. Because different cytokine profiles are associated with distinct arms of the immune response, testing in the ELISPOT assay may also help us understand the mechanisms responsible.
Subject(s)
Lymphocyte Activation , Neoplasms/metabolism , Peptides/chemistry , T-Lymphocytes/metabolism , Antigen-Presenting Cells/metabolism , Cells, Cultured , Colonic Neoplasms/metabolism , Cytokines/metabolism , Dose-Response Relationship, Drug , Humans , Interferon-gamma/metabolism , Leukocytes, Mononuclear/metabolism , Peptides/metabolismABSTRACT
Several issues remain to be resolved before the efficacy of various approaches to elicit anti-tumor immunity in patients can be evaluated. First, in vitro assays able to detect responses by T cells primed in vivo are needed. Second, a source of tumor antigen to stimulate patients' lymphocytes in vitro is required. The ELISPOT assay is attractive, because it can be performed with a small numbers of cells and requires only short-term culture in vitro. A source of tumor antigen is more problematic, since for most tumors, tumor-associated antigens (TAA) have not been identified and/or cloned. In this report we demonstrate that autologous antigen-presenting cells (APC) pulsed with total tumor peptides from autologous tumor tissue can stimulate IFNgamma release by patients' lymphocytes in the ELISPOT assay. Thus, this approach should be considered for monitoring immune responses in clinical immunotherapy trials.
Subject(s)
Antigens, Neoplasm/immunology , Enzyme-Linked Immunosorbent Assay/methods , Interferon-gamma/metabolism , Lymphocytes/immunology , Neoplasms/immunology , Peptides/immunology , Antigen Presentation , Antigen-Presenting Cells , Dose-Response Relationship, Drug , Humans , Immunotherapy , Neoplasms/therapyABSTRACT
INTRODUCTION: In previous studies we described mechanisms by which acute elevation of the intraabdominal pressure (IAP) induces intracranial hypertension (ICHTN). Here we sought to define the role of ICHTN in mediating systemic hypertension (HTN) during CO(2) pneumoperitoneum (PNP). METHODS: Six large animals (swine) were hyperventilated to buffer hypercarbia. Intracranial pressure (ICP) was monitored with a Camino intraparenchymal ICP monitoring system. A Foley catheter was introduced intracranially via a separate burr hole. At phase 1, changes in ICP, central venous pressure (CVP), and mean arterial pressure (MAP) were recorded during periods of CO(2) PNP at IAP levels of 15, 20, 25, and 30 mm Hg. At phase 2, ICHTN was produced directly by inflating the intracranial balloon to the same ICP levels that had been measured in phase 1 for each degree of IAP. CVP and MAP were recorded. Repeated measures analysis of variance was applied. RESULTS: At phase 1, the mean DeltaCVP, DeltaICP, and DeltaMAP increased relative to the degree of IAP (P = 0.0001, 0.0004, and 0.024, respectively). At phase 2, the increments in DeltaMAP were significant (P = 0.024) and in the same direction and amplitude as at phase 1. CONCLUSIONS: In this study, increasing the IAP with CO(2) PNP with a consequent increase of ICP and direct manipulation of the ICP produced a comparable systemic HTN. We believe that this further supports our hypothesis: Elevated IAP produces an immediate increase in the CVP, which impairs venous drainage from the central nervous system (CNS), increases the ICP, and initiates a CNS-mediated response and systemic HTN.
Subject(s)
Abdomen/physiology , Hypertension/physiopathology , Animals , Blood Pressure , Carbon Dioxide , Central Venous Pressure , Female , Hypertension/etiology , Intracranial Pressure , Pneumoperitoneum, Artificial , Pressure , Radiography , Swine , Vena Cava, Inferior/diagnostic imaging , Vena Cava, Inferior/physiopathologyABSTRACT
BACKGROUND: The success of immunomodulatory cancer therapy is frequently hampered by the transient nature of the antitumor immune response. We have shown previously in a mouse model that interleukin 12 (IL-12) generates a strong natural killer (NK) cell-mediated antitumor response and reduces liver metastases induced by a colon carcinoma cell line. However, only a small percentage of the treated animals developed the cytotoxic T-lymphocytic response required for a long-term systemic antitumor immunity. 4-1BB is a co-stimulatory molecule expressed on the surface of activated T cells. Interaction of 4-1BB with its natural ligand (4-1BBL) has been shown to amplify T-cell (especially CD8+)-mediated immunity. In this study, we investigated the effects of adenovirus-mediated gene therapy delivering both IL-12 and 4-1BBL genes on mice with hepatic metastases induced by colon cancer cells. METHODS: Syngeneic BALB/c mice received intrahepatic injection of poorly immunogenic MCA26 colon cancer cells. Various combinations of replication-defective adenoviruses expressing IL-12 and 4-1BBL genes were injected into the established liver tumors. Changes in tumor size and animal survival were then monitored. All statistical tests were two-sided. RESULTS: The long-term survival rate of mice treated with the combination of IL-12 and 4-1BBL was significantly improved over that of animals in the control group (P =.0001). In vivo depletion of NK cells or CD8+ T cells completely abolished the long-term survival advantage of the IL-12 plus 4-1BBL-treated animals (P<.002). Moreover, the systemic immunity induced by this combination treatment protected these animals against a subcutaneous challenge with parental MCA26 cells. CONCLUSION: Adenovirus-mediated transfer of IL-12 and 4-1BBL genes directly into liver tumors resulted in tumor regression that required both NK and CD8+ T cells and generated a potent, long-lasting antitumor immunity.
Subject(s)
Adjuvants, Immunologic/therapeutic use , CD8-Positive T-Lymphocytes/immunology , Genetic Therapy/methods , Interleukin-12/therapeutic use , Killer Cells, Natural/immunology , Liver Neoplasms/immunology , Liver Neoplasms/therapy , Tumor Necrosis Factor-alpha/therapeutic use , 4-1BB Ligand , Adenoviridae , Adjuvants, Immunologic/genetics , Animals , Colonic Neoplasms/pathology , Disease Models, Animal , Female , Genetic Vectors , Interleukin-12/genetics , Liver Neoplasms/genetics , Liver Neoplasms/secondary , Mice , Mice, Inbred BALB C , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/geneticsABSTRACT
Inhibition of angiogenesis has been shown to be an effective strategy in cancer therapy in mice. However, its widespread application has been hampered by difficulties in the large-scale production of the antiangiogenic proteins. This limitation may be resolved by in vivo delivery and expression of the antiangiogenic genes. We have constructed a recombinant adenovirus that expresses murine endostatin that is biologically active both in vitro, as determined in endothelial cell proliferation assays, and in vivo, by suppression of angiogenesis induced by vascular endothelial growth factor 165. Persistent high serum levels of endostatin (605-1740 ng/ml; mean, 936 ng/ml) were achieved after systemic administration of the vector to nude mice, which resulted in significant reduction of the growth rates and the volumes of JC breast carcinoma and Lewis lung carcinoma (P < 0.001 and P < 0.05, respectively). In addition, the endostatin vector treatment completely prevented the formation of pulmonary micrometastases in Lewis lung carcinoma (P = 0.0001). Immunohistochemical staining of the tumors demonstrated a decreased number of blood vessels in the treatment group versus the controls. In conclusion, the present study clearly demonstrates the potential of vector-mediated antiangiogenic gene therapy as a component in cancer therapy.
Subject(s)
Collagen/genetics , Collagen/toxicity , Gene Transfer Techniques , Lung Neoplasms/pathology , Mammary Neoplasms, Experimental/pathology , Neovascularization, Pathologic/prevention & control , Peptide Fragments/genetics , Peptide Fragments/toxicity , Adenoviridae , Animals , Antineoplastic Agents/toxicity , Cell Division/drug effects , Cloning, Molecular , Collagen/biosynthesis , Endostatins , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Female , Fibroblast Growth Factor 2/pharmacology , Genetic Therapy/methods , Genetic Vectors , Humans , Liver/metabolism , Lung Neoplasms/blood supply , Lung Neoplasms/drug therapy , Mammary Neoplasms, Experimental/blood supply , Mammary Neoplasms, Experimental/drug therapy , Mice , Mice, Inbred BALB C , Neoplasm Metastasis/prevention & control , Peptide Fragments/biosynthesis , Tumor Cells, Cultured , Umbilical VeinsABSTRACT
BACKGROUND: The biologic activity of vitamin A depends, in part, on its metabolism to active nuclear receptor ligands, chiefly retinoic acid. The cellular retinol-binding protein (CRBP) binds vitamin A with high affinity and is postulated to regulate its uptake and metabolism. In this report, we analyze the expression of CRBP in normal and malignant breast tissues. METHODS: We evaluated CRBP expression by in situ hybridization in six reduction mammoplasty specimens and 49 human breast carcinoma specimens by use of digoxigenin-labeled RNA probes and in nine cultured mammoplasty specimens by northern or western blot analysis. Statistical significance was evaluated with the chi(2) test or Fisher's exact test if the sample sizes were small. All P values are from two-sided tests. RESULTS: CRBP was expressed in all 15 mammoplasty specimens (normal breast tissue) and in 33 of 35 available specimens of normal tissue adjacent to carcinoma. In contrast, 12 (24%) of 49 carcinoma lesions were uniformly negative for CRBP (P =.023 for comparison with adjacent normal breast tissue). The loss of CRBP expression was as frequent in ductal carcinoma in situ (six [27%] of 22) as in invasive lesions (six [22%] of 27), suggesting that it is a relatively early event in carcinogenesis and not associated with patient age, tumor grade, and expression of steroid receptors or c-Myc. Preliminary experiments did not find an association between CRBP and retinoic acid receptor beta loss, but most (four of five) CRBP-negative tumors were also retinoic acid receptor beta negative. CONCLUSION: CRBP is underexpressed in 24% (95% confidence interval = 12.5%-36.5%) of human breast carcinomas, implying a link between cellular vitamin A homeostasis and breast cancer. We hypothesize that the loss of CRBP restricts the effects of endogenous vitamin A on breast epithelial cells.
Subject(s)
Breast Neoplasms/chemistry , Carcinoma in Situ/chemistry , Carcinoma, Ductal, Breast/chemistry , Receptors, Retinoic Acid/analysis , Retinol-Binding Proteins/analysis , Signal Transduction , Tretinoin/analysis , Vitamin A/analysis , Blotting, Northern , Breast/metabolism , Breast Neoplasms/pathology , Carcinoma in Situ/pathology , Carcinoma, Ductal, Breast/pathology , DNA, Complementary , Female , Gene Expression Regulation, Neoplastic , Genes, myc , Humans , In Situ Hybridization , Mammaplasty , RNA, Neoplasm/chemistry , Retinol-Binding Proteins/genetics , Retinol-Binding Proteins, CellularABSTRACT
We previously reported that a 660-bp sequence that is homologous to the env gene of the mouse mammary tumor virus (MMTV) but not to endogenous retroviruses or to other known genes was present in 38% of human breast cancers and in some breast cancer cell lines studied (Y. Wang et al., Cancer Res., 55: 5173-5179, 1995). Here, we have investigated whether the MMTV-like sequences were associated with the clinical, pathological, and molecular parameters that have been reported to define two subsets of human breast cancers. Archival breast carcinoma samples were analyzed for four clinical parameters, obtained from patients' records, and for six pathological characteristics. Expression of c-erbB-2, p53, bcl-2, progesterone receptor, laminin receptor, and cathepsin D was detected by immunochemistry using monoclonal antibodies. PCRs were used to amplify 250 bp of the MMTV env gene-like sequence. The chi2, log-rank, and generalized Wilcoxon tests were used to analyze the data. The MMTV env gene-like sequence was detected in 37.7% of the samples. The presence of this sequence was not significantly associated with any of the pathological clinical or biological parameters studied. It did correlate, however, with expression of the laminin receptor, a marker for invasiveness and poor prognosis. This is the first phenotypic characterization of human breast cancers containing retroviral sequences.
Subject(s)
Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , Genes, env/genetics , Mammary Tumor Virus, Mouse/genetics , Receptors, Laminin/biosynthesis , Breast Neoplasms/metabolism , Breast Neoplasms/mortality , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/mortality , Carcinoma, Ductal, Breast/surgery , Disease-Free Survival , Female , Humans , Immunohistochemistry , Middle Aged , Neoplasm Invasiveness , Sequence Homology, Nucleic Acid , Survival RateABSTRACT
Interleukin-12 (IL-12) is a 70-kDa heterodimeric cytokine composed of a 35-kDa subunit (p35) and a 40-kDa subunit (p40). We have demonstrated previously that intratumoral delivery of a recombinant adenoviral vector expressing the mouse IL-12 gene significantly prolongs the survival time of mice with metastatic colon carcinoma in the liver. We now report the molecular cloning of cDNA for both subunits of human IL-12 (hIL-12) in a recombinant adenoviral vector in which the p40 and p35 subunits are linked and coexpressed using the encephalomyocarditis virus internal ribosome entry site. The recombinant adenoviral vector was used to transduce human tumor cell lines, and the presence of hIL-12 in the conditioned media was illustrated by enzyme-linked immunosorbent assay. The biological activity of hIL-12 in the conditioned media was also demonstrated in vitro through its ability to induce interferon-gamma production from peripheral blood mononuclear cells (PBMCs), to stimulate PBMC proliferation, and to enhance natural killer activity from normal human PBMCs to lyse natural killer-sensitive K562 target cells. The results of these studies support the application of this recombinant adenoviral vector construct as an efficient gene delivery vehicle in phase I/II clinical studies of hIL-12 gene therapy for cancer.
Subject(s)
Adenoviridae/genetics , Genetic Vectors , Interleukin-12/genetics , Animals , Base Sequence , Cell Line , DNA Primers , Humans , Mice , Recombinant Proteins/genetics , Recombination, Genetic , Transduction, Genetic , Tumor Cells, CulturedABSTRACT
Snoring occurs commonly in children and is sometimes associated with obstructive sleep apnea syndrome (OSAS). Based on clinical history alone, it is difficult to distinguish primary snoring, characterized by noisy breathing during sleep without apnea or hypoventilation, from snoring indicative of OSAS. An overnight polysomnogram (PSG) is required to establish a definitive diagnosis of OSAS. Because sleep evaluations are costly and resources are limited, we evaluated whether a home audiotape recording could accurately identify children with OSAS. We studied 36 children referred by pediatricians and otolaryngologists for possible OSAS. Parents completed a questionnaire about their child's sleep and breathing and made a 15-min audiotape of the child's breath sounds during sleep. Overnight PSGs were performed on all patients. There were 29 patients who completed the study: 15 patients in the Primary Snoring group (apnea/hypopnea index < 5) and 14 patients in the OSAS group (apnea/hypopnea index > or = 5). No significant statistical differences existed between the two groups for physical characteristics or questionnaire responses. Seven observers analyzed the audiotapes for the presence of a struggle sound and respiratory pauses. The median sensitivity of the audiotape as a predictor of OSAS was 71% (range 43-86%), and the median specificity was 80% (range 67-80%). The presence of a struggle sound on the audiotape was the parameter most predictive of OSAS. There was a good level of agreement among the seven audiotape observers, as demonstrated by a mean and range kappa statistic of 0.70 (0.50-0.93) for the 21 pairs of observers. Using a clinical score to predict OSAS, the sensitivity was 46%, and the specificity was 83%. We conclude that findings on a home audiotape can be suggestive of OSAS, but are not sufficiently specific to reliably distinguish primary snoring from OSAS.
Subject(s)
Sleep Apnea Syndromes/diagnosis , Tape Recording , Child , Child, Preschool , Diagnosis, Differential , Evaluation Studies as Topic , Female , Humans , Male , Polysomnography , Predictive Value of Tests , Sensitivity and Specificity , Snoring/diagnosis , Surveys and QuestionnairesABSTRACT
PURPOSE: Recombinant human interleukin-6 (rhuIL-6) is a glycosylated cytokine with hematopoietic stimulatory effects. In particular, preclinical studies suggest the agent can stimulate thrombopoiesis, even in conjunction with chemotherapy. We attempted to determine whether higher dose chemotherapy for ovarian cancer was possible given the pharmacologic use of this important growth factor. METHODS: We conducted a randomized, double-blind phase II study of IL-6 plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in combination with a standard chemotherapy regimen. Patients with epithelial ovarian cancer, stages Ic to IV, were eligible. All patients were previously untreated with chemotherapy and had Karnofsky performance status >/=60. rhuIL-6 (Escherichia coli, SDZ ILS 969) 1.0 micrograms/kg or placebo was given subcutaneously on days 2-8 every cycle together with G-CSF 5.0 micrograms/kg subcutaneously days 2-15, following administration of paclitaxel 175 mg/m2 as a 3-h infusion and carboplatin given to a desired AUC of 7.5 on day 1 every 21 days. RESULTS: Fifty patients were entered in this study, although the study was temporarily suspended by the FDA in midstudy over manufacturing concerns. Therefore, 37 patients were evaluable for efficacy of growth factor; 19 patients received placebo plus G-CSF and 18 rhIL-6 plus G-CSF. There was no difference in prognostic variables between these two groups. Platelet nadirs were lower in the first cycle for the placebo group (P = 0.004, Wilcoxon sum-rank test) but not in other cycles. There was no statistically significant difference in cycle treatment delays, carboplatin dose delivered, number of patients with grade 4 thrombocytopenia, or platelet transfusion. Nonetheless, the trend of the data favored IL-6 in all cases. CONCLUSIONS: This study demonstrated a minimal effect (statistically significant in the first cycle only) on thrombopoiesis in women undergoing paclitaxel and carboplatin therapy of ovarian cancer. No clinically significant effect on actual chemotherapy delivery was demonstrated, however. Future studies, if warranted, to ameliorate thrombocytopenia should be carried out with regimens producing even greater thrombocytopenia than the current regimen in the control arm.
Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Granulocyte Colony-Stimulating Factor/administration & dosage , Interleukin-6/administration & dosage , Ovarian Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Carboplatin/administration & dosage , Double-Blind Method , Drug Administration Schedule , Female , Humans , Karnofsky Performance Status , Middle Aged , Paclitaxel/administration & dosage , Recombinant Proteins/administration & dosageABSTRACT
BACKGROUND AND OBJECTIVES: Malignant mesothelioma has a poor prognosis and is refractory to many agents. The antitumor effectiveness of cisplatin, paclitaxel, and suramin as single agents and in combination was evaluated in vivo against four lines of human pleural malignant mesothelioma xenografts in athymic nude mice, including one epithelial type and three fibrosarcomatous. METHODS: After growth of tumors occurred by day 54 or 55, mice were randomized in groups of four each to receive either cisplatin 4 mg/kg intraperitoneally weekly x5, or paclitaxel (Taxol) 12.5 mg/kg subcutaneously daily 5 days/week for 3 consecutive weeks, or suramin 60 mg/kg intraperitoneally daily x4,versus controls treated with normal saline. RESULTS: Cisplatin was very effective against one line and also to a lesser degree against another line. Paclitaxel showed antitumor effects similar to cisplatin, being very effective in one line, and also showed good activity in another line. Suramin was basically inactive in all four lines. Following the results obtained with these single agents, it was decided to evaluate the combination of cisplatin and paclitaxel, which resulted in more pronounced antitumor effect in all four cell lines. CONCLUSIONS: These results indicate that the combination of cisplatin and paclitaxel is superior to each agent alone in this model, and that it deserves to be evaluated in patients with malignant mesothelioma.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Mesothelioma/drug therapy , Pleural Neoplasms/drug therapy , Animals , Cisplatin/administration & dosage , Drug Administration Schedule , Female , Fibrosarcoma/pathology , Humans , Mesothelioma/pathology , Mice , Mice, Nude , Neoplasm Transplantation , Paclitaxel/administration & dosage , Pleural Neoplasms/pathology , Sarcoma/pathology , Suramin/administration & dosage , Transplantation, Heterologous , Tumor Cells, Cultured/drug effectsSubject(s)
Cyclosporins/therapeutic use , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Ovarian Neoplasms/drug therapy , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Female , Humans , Paclitaxel/pharmacology , Paclitaxel/therapeutic use , Prospective Studies , Salvage Therapy , Treatment OutcomeABSTRACT
BACKGROUND: Pathologic evidence of pelvic lymph node involvement is obtained in 12%-20% of patients with localized prostate cancer that exhibits high-risk features (defined on the basis of tumor size, serum prostate-specific antigen [PSA] level, or Gleason score). The rate of systemic failure (i.e., relapse) in patients with this type of prostate cancer and no pathologic evidence of regional lymph node involvement is 55%-92% within 5 years of definitive local therapy. Since reverse transcription-polymerase chain reaction (RT-PCR) methods are likely to be more sensitive than routine pathologic examination in detecting metastatic tumor cells, we compared the ability of the two approaches to detect prostate cells in the pelvic lymph nodes of patients with localized, high-risk disease. METHODS: Fifty-eight lymph node specimens isolated from 33 patients before definitive local therapy were examined. Expression of PSA and prostate-specific membrane antigen (PSM) messenger RNAs in the specimens was assessed by means of nested RT-PCR. RESULTS: Pathologic examination identified tumor cells in the lymph nodes of four (12%) of the 33 patients, and PSA and/ or PSM expression was positive in specimens from 27 (82%) of the patients (two-sided P<.0001). The four patients with positive pathologic findings also had positive RT-PCR results. Among the 29 patients with no pathologic evidence of lymph node involvement, 23 (79%) tested positive by means of RT-PCR. In these 23 patients, PSM expression was detected more frequently than PSA expression; however, in two patients, only PSA expression was detected. CONCLUSIONS: Expression of prostate-specific markers in the pelvic lymph nodes of patients with localized, high-risk prostate cancer may indicate the presence of metastatic tumor cells. Such cells may be responsible for the high rate of systemic failure seen in these patients. Additional studies are required to determine the prognostic relevance of our findings.